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Human Luteinizing Hormone and 
Chorionic Gonadotropin Display 
Biased Agonism at the LH and LH/
CG Receptors
Laura Riccetti1, Romain Yvinec2, Danièle Klett2, Nathalie Gallay2, Yves Combarnous2, Eric 
Reiter2, Manuela Simoni1,4,5, Livio Casarini1,4 & Mohammed Akli Ayoub2,3,6
Human luteinizing hormone (LH) and chorionic gonadotropin (hCG) have been considered biologically 
equivalent because of their structural similarities and their binding to the same receptor; the LH/CGR. 
However, accumulating evidence suggest that LH/CGR differentially responds to the two hormones 
triggering differential intracellular signaling and steroidogenesis. The mechanistic basis of such 
differential responses remains mostly unknown. Here, we compared the abilities of recombinant rhLH 
and rhCG to elicit cAMP, β-arrestin 2 activation, and steroidogenesis in HEK293 cells and mouse Leydig 
tumor cells (mLTC-1). For this, BRET and FRET technologies were used allowing quantitative analyses 
of hormone activities in real-time and in living cells. Our data indicate that rhLH and rhCG differentially 
promote cell responses mediated by LH/CGR revealing interesting divergences in their potencies, 
efficacies and kinetics: rhCG was more potent than rhLH in both HEK293 and mLTC-1 cells. Interestingly, 
partial effects of rhLH were found on β-arrestin recruitment and on progesterone production compared 
to rhCG. Such a link was further supported by knockdown experiments. These pharmacological 
differences demonstrate that rhLH and rhCG act as natural biased agonists. The discovery of novel 
mechanisms associated with gonadotropin-specific action may ultimately help improve and personalize 
assisted reproduction technologies.
Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) are two heterodimeric glycoprotein hor-
mones playing key roles in human reproduction. They are produced by the pituitary gland (LH) and placenta 
(hCG) and circulate as mixtures of differentially glycosylated isoforms which present different half-lives and bio-
activities1–3. Both hCG and hLH bind to luteinizing hormone/choriogonadotropin hormone receptor (LH/CGR) 
in human and LHR in non-human species which are mainly expressed in the ovary and testis. In normal female 
cycle, LH is involved in late follicular maturation and ovulation and it also triggers corpus luteum steroidogenic 
activity. hCG is responsible for maintaining steroidogenic activity by corpus luteum over the first four months of 
pregnancy in women. hCG also inhibits LH and FSH secretion and triggers steroidogenesis in fetal gonads4, 5. LH/
CGR belongs to a subgroup of class A (rhodopsin-like) G protein-coupled receptors (GPCRs) characterized by 
the presence of multiple leucine-rich repeats (LRRs) in their extracellular amino-terminal domain. Regarding its 
signaling, LH/CGR is known to mediate the canonical G protein-mediated signaling pathway through coupling 
to heterotrimeric Gαs protein which activates adenylate cyclase. It results in cAMP accumulation and activation 
of protein kinase A (PKA), as well as in the exchange protein directly activated by cAMP (EPAC). This, in turn, 
triggers the activation of multiple downstream kinases that modulate the nuclear activity of cAMP response 
element-binding protein (CREB) and the expression of the genes involved in the physiological responses to 
these hormones. Besides, LH/CGR was one of the first GPCRs shown to independently activate two G proteins, 
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leading to both adenylyl cyclase and phospholipase C activation through functional coupling to Gαs and Gαq, 
respectively6, 7. More recently, LH/CGR has been also reported to engage a multiplicity of G protein-independent 
pathways8 including β-arrestin-dependent pathways9–11. For many years, β-arrestins have been considered exclu-
sively as silencers of the GPCRs signaling, prompting ligand-induced receptor internalization and trafficking12, 13. 
Now it is well recognized that β-arrestins regulate GPCR signaling and trafficking and are also able to engage 
G protein-independent signaling, the most studied of which being ERK1/2 pathway12–14. The implication of 
β-arrestins in trafficking and signaling of gonadotropin receptors has also been reported11, 15–21.
For many years, LH and hCG have been assumed to be equivalent, even though distinct physiological5, 22, 
molecular23, 24 and pharmacological25, 26 features were described3, 27. Importantly, the phenomenon of biased sig-
naling implies that the binding of a given ligand can stabilize a subset of activated conformations of the receptor 
thereby leading to a selective modulation of downstream signaling pathways. This has been reported for numer-
ous GPCRs14, 28–30. In line with this emerging concept, it has been recently proposed that LH and hCG produced 
as multiple glycosylated isoforms could potentially trigger selective transduction mechanisms at the LH/CGR1, 
8. Recent lines of evidence support this hypothesis, showing that, although their structures are similar and they 
shared the same receptor, LH and hCG elicit divergent signaling in several cell models27. A genomic deletion 
resulting in the complete absence of exon 10 of LH/CGR found in a hypogonadic patient with type II Leydig cell 
hypoplasia31 impaired LH-, but not hCG-induced cAMP production, without affecting ligand binding32. More 
recently, it has been reported in human granulosa cells that hCG displays higher potency than LH on the cAMP/
PKA pathway as well as on steroidogenesis, whereas LH is more potent than hCG on ERK1/2 and Akt phospho-
rylation as well as on related gene expression33. The proliferative and steroidogenic/pro-apoptotic effects mediated 
by LH and hCG in vitro, respectively, are amplified by FSH co-treatment34. In fact, in goat ovarian granulosa cells, 
prolonged LH treatment promotes growth and proliferation whereas hCG leads to higher levels of cAMP and 
decreased proliferation35.
Despite these recent advances, the potential of hCG and LH to differentially activate Gαs and 
β-arrestin-dependent pathways at the LH/CGR and LHR has not been evaluated. In addition, the relative con-
tributions of these transduction mechanisms to steroidogenesis are still unknown. In the present study, we used 
a series of bioluminescence and time-resolved resonance energy transfer (BRET and TR-FRET) and reporter 
assays to quantitatively assess the signaling promoted by rhCG and rhLH in real-time and living cells as previ-
ously reported10, 11. The canonical Gαs/cAMP pathway as well as β-arrestin 2 recruitment were analyzed upon 
the activation of human LH/CGR transiently expressed in HEK293 cells or LHR endogenously expressed in 
murine Leydig tumor cell line (mLTC-1)11, 36. In addition, the degree of bias between rhCG- and rhLH-mediated 
responses was quantified using the operational model of Black and Leff37 and previously detailed procedures11, 38.
Materials and Methods
Recombinant gonadotropins. Human recombinant LH (Luveris®) and rhCG (Ovitrelle®) were kindly 
provided by Merck KGaA (Darmstadt, Germany). Molar concentrations of the recombinant rhCG and rhLH were 
calculated based on their respective specific activities (6500 and 5360 IU) and molecular weights (37 and 30 kDa).
Cell Culture and Transfection. HEK293 cells were grown in complete DMEM medium supplemented 
with 10% (v/v) fetal bovine serum, 4.5 g/l glucose, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 1 mM glu-
tamine (Invitrogen, Carlsbad, CA, USA). mLTC-1 cells (ATCC CRL-2065, LCG Standards, Molsheim, France) 
were grown in complete RPMI medium supplemented with 10% (v/v) fetal bovine serum, 50 µg/ml gentamicin, 
10 units/ml penicillin and 10 µg/ml streptomycin. Transient transfections were performed by reverse transfection 
in 96-well plate using Metafectene PRO (Biontex, München, Germany) following the manufacturer’s protocol and 
using 105 cells, 100 ng of total plasmids and 0.5 µl of Metafectene PRO per well.
Small interfering RNA transfection. The siRNA sequence 5′-AAAGCCUUCUGUGCUGAGAAC-3′ 
was used to target mouse β-arrestin 1 (position 439–459 relative to the start codon) whereas sequence 
5′-AAACCUGUGCCUUCCGCUAUG-3′ was used to target mouse β-arrestin 2 (position 175–193 
relative to the start codon)39. One small RNA duplex with no silencing effect was used as a control 
(5′-UUCUCCGAACGUGUCACGU-3′). The siRNAs were synthesized by GE Healthcare Dharmacon 
(Velizy-Villacoublay, France). Early passage mLTC-1 cells at 30% confluency in 100 mm dishes were transiently 
transfected with GeneSilencer following the manufacturer’s recommendations (Genlantis, San Diego, CA, USA). 
Forty-eight hours after transfection, cells were seeded into assay plates. All assays were performed three days after 
transfection.
BRET sensors. In order to measure cAMP real-time response in living cells, HEK293 cells were transiently 
transfected with two plasmids coding for hLH/CGR (kindly provided by A. Ulloa-Aguirre, Universidad Nacional 
Autónoma de México, México) and the BRET-based cAMP sensor CAMYEL (kindly provided by L.I. Jiang, 
University of Texas, Texas, USA) as previously reported10, 11. For mLTC-1 cells, only CAMYEL plasmid was trans-
fected since they naturally express the endogenous LHR.
For the assessment of β-arrestin 2 recruitment, HEK293 cells were transiently co-transfected with plasmids 
coding for hLH/CGR C-terminally fused to the BRET donor Rluc8 (kindly provided by Dr. A. Hanyaloglu, 
Imperial College, London, UK) and for β-arrestin 2 N-terminally fused to the BRET acceptor yPET (kindly 
provided by Dr. M.G. Scott, Cochin Institute, Paris, France). Upon rhCG and rhLH stimulation, β-arrestin 
2 translocates to the receptor, leading to energy transfer between Rluc8 and yPET, and as a consequence, to 
dose-dependent increases in BRET signals. The conformational rearrangements within β-arrestin 2 were meas-
ured using β-arrestin 2 double brilliance sensor40–42. For this, HEK293 cells were transiently co-transfected with 
the plasmids coding for hLH/CGR and for Rluc8-β-arrestin 2-RGFP fusion protein (kindly provided by Dr. R. 
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Jockers, Cochin Institute, Paris, France). Then, changes in intramolecular BRET signals within sensor were mon-
itored upon cell stimulation with increasing doses of rhCG and rhLH.
Cell stimulations and BRET measurements. For the end-point dose-response experiments, medium 
was aspirated and cells were re-suspended in 40 µl/well of PBS 1X, 1 mM HEPES. Cells were incubated for 30 min-
utes at 37 °C in a total volume of 40 µl/well of PBS 1X, 1 mM HEPES containing or not increasing concentrations 
of rhCG and rhLH. BRET measurements were performed upon addition of 10 µl/well of 5 µM Coelenterazine 
h (Interchim, Montluçon, France), using Mithras LB 943 plate reader (Berthold Technologies GmbH & Co. 
Wildbad, Germany). For the real-time kinetics, cells were re-suspended in 60 µl/well of PBS 1X, 1 mM HEPES 
and, for cAMP kinetics, 200 µM IBMX. BRET measurement was immediately performed upon addition of 20 µl/
well of EC50 concentrations of rhCG and rhLH as previously calculated in dose-response experiments, and 20 µl/
well of coelenterazine h.
Cre-dependent reporter assay. HEK293 cells were transiently transfected with hLH/CGR and the 
pSOM-Luc plasmid expressing the firefly luciferase reporter gene under the control of the cAMP Responsive 
Element of the somatostatin promoter region43. mLTC-1 cells were transiently transfected with the pSOM-Luc 
plasmid alone. After 48-hours, cells were split into 96-well plates. The day after, cells were stimulated 6 hours with 
increasing doses of hormones, then washed twice with ice-cold PBS and lysed in 200 µl of lysis buffer (Promega, 
Madison, WI, USA). Luciferase activity was measured using the luciferase assay system supplied by Promega. An 
aliquot (20 µl) of each sample was mixed with 50 µl of luciferase assay reagent and the emitted light was measured 
in Mithras LB 943 plate reader. Values were expressed in relative luciferase activity units (RLU).
Steroid measurements. Progesterone and testosterone levels were measured in the supernatants of 
mLTC-1 cells cultured in complete RPMI medium. For progesterone, cells were first seeded in 48-well plates (105 
cells/well) for three days and then re-suspended in serum-free RPMI for one hour and stimulated or not with 
increasing doses of rhCG and rhLH for 3 hours. Cell supernatants were collected and stored at −20 °C until analy-
sis. Progesterone production was measured with a home-made competitive ELISA assay44. Briefly, a 96-wells plate 
was coated overnight at 4 °C with a goat anti-mouse IgG antibody, 10 ng/well (UP462140, Interchim, Montluçon, 
France). After three washes in PBS 1X containing 0.1% Tween 20, non-specific sites were saturated 1 hour with 
200 µl/well of PBS-Tween 20 supplemented with 0.2% BSA. Standard progesterone (Q2600, Steraloids, USA) in 
PBS-Tween 20-BSA or mLTC-1 cells supernatants (25 µl per well of 1:50 or 1:100 dilution) were then plated on the 
empty plate. Progesterone-11-Hemisuccinate-HRP (Interchim) were added, together with 36 ng/well of mouse 
anti-P4 antibody (AbD Serotec, Biogenesis, Interchim). The plate was incubated for 4 hours at room temperature, 
washed and 100 µl/well of TMB ELISA substrate standard solution (Interchim) was added. The mixture was incu-
bated for 20 min at room temperature in the dark. The reaction was stopped with 2 N H2SO4 and absorbance was 
measured at 450 nm using SunriseTM absorbance reader (Tecan, France).
Testosterone levels were measured by using an HTRF®-based assay kit (CisBio Bioassays, Codolet, France) 
following the manufacturer’s protocol and as previously described11. Briefly, cells were seeded in 96-well plate 
(104 cells/well), starved overnight in serum-free RPMI medium and incubated 3 hours at 37 °C in 100 µL/well 
of serum-free RMPI medium containing or not increasing concentrations of rhCG and rhLH. Then 10 µl of cul-
ture supernatants were transferred into 384-well and mixed with 10 µl of a mixture of HTRF mix containing an 
anti-testosterone antibody and testosterone labeled with Terbium and d2 fluorophores, respectively. TR-FRET sig-
nals were detected using Mithras LB 943 plate reader (Berthold Technologies GmbH & Co. Wildbad, Germany).
cAMP HTRF-based assay. Intracellular cAMP levels were measured using a homogeneous time-resolved 
fluorescence (HTRF®) assay kit (CisBio Bioassays)10, 11 according to the manufacturer’s instructions.
Data analysis. BRET data were represented as “Induced BRET Changes” by subtracting the 540 nm/480 nm 
ratio of the non-treated cells from the same ratio of cells stimulated with increasing doses of rhCG and rhLH. 
The % of responses in BRET and steroid measurement were obtained by taking as 100% the maximal response 
of rhCG at 10 nM in the different assays. All the results were fitted following the appropriate nonlinear regres-
sion equations using GraphPad Prism software (San Diego, CA, USA). Statistical analyses were performed with 
unpaired t-test (for the Emax and EC50 values) in HEK293 and mLTC-1 cells and Two-way ANOVA (for siRNA 
β-arrestin data in mLTC-1 cells), both using the GraphPad Prism software.
Bias calculation. The bias factor (B.F.) was obtained after statistical fitting of the data to the operational 
model reported by Black and Leff37, as previously reported11.
Results
LH/CGR-promoted cAMP Response. To compare the respective efficacies and potencies of rhCG and 
rhLH, we first assessed the ability of either hormone to elicit the accumulation of cAMP, the prototypical second 
messenger produced upon coupling and activation of the heterotrimeric Gαs protein by LH/CGR. For this pur-
pose, HEK293 cells transiently co-expressing human LH/CGR and the BRET-based cAMP sensor (CAMYEL) 
were used as previously reported10, 11. Changes in BRET signal were monitored in living cells after 30 minutes of 
incubation with increasing doses of rhCG and rhLH. As expected, both hormones showed very potent effects 
on the cAMP signaling pathway with EC50 values in the pM range as previously shown10, 11 (Fig. 1A) (Table 1). 
Consistent with previous reports, the rhCG dose-response curve is significantly shifted towards the lower doses 
compared to that of rhLH33. Indeed, the EC50 values of rhCG response was found approximately 16 times lower 
than that of rhLH (p < 0.0001; n = 7) (Table 1). By contrast, at the saturating doses both hormones promoted sim-
ilar maximal cAMP responses indicating that both act as full agonists on LH/CGR-promoted cAMP production. 
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We also investigated cAMP accumulation in real-time kinetics by stimulating cells with different concentrations 
(0.05, 0.5, and 5 nM) of rhCG and rhLH to cover the EC50 and sub-maximal doses according to the dose curves 
shown in Fig. 1A. As shown in Fig. 1B, a relationship between the doses and the kinetics was observed with 
faster and saturating responses obtained when increasing doses were used. Indeed, when rhCG and rhLH were 
compared at their respective sub-saturating doses (i.e.: 0.01 nM for rhCG and 0.5 nM for rhLH), both promoted 
a rapid cAMP response with no difference in their kinetics (t1/2 around 1 min) (Fig. 1B). The response reached a 
plateau even after 30 minutes of stimulation (Fig. 1B) and this cannot be due to a saturation of the cAMP response 
in our system. In fact, at a higher and saturating dose of both hormones (5 nM), the cAMP response was further 
increased with faster (t1/2 value around 0.5 min) and equivalent kinetics for both hormones (Fig. 1B).
To investigate the cAMP pathway on endogenously expressed LHR, we used a mouse Leydig tumor cell line 
(mLTC-1)45 either transfected with CAMYEL sensor (Fig. 1C) or not (Fig. 1D), as previously reported10, 11. Again, 
BRET measurements revealed rhCG dose-response curve shifted towards the lower doses compared to rhLH 
(Fig. 1C). Specifically, the EC50 value of rhCG was approximately 6 times lower than that of rhLH (p = 0.0067; 
n = 5) (Table 2). To further confirm these data and to exclude any artifact due to the transfection of CAMYEL 
sensor in mLTC-1 cells, we also measured cAMP levels in native cells using HTRF-based assay, which does not 
require any cell transfection. We found a similar pattern of rhCG- and rhLH-induced cAMP responses (Fig. 1D). 
Figure 1. LH/CGR-mediated cAMP production. cAMP responses induced by rhCG and rhLH in HEK293 cells 
transiently co-expressing hLH/CGR and CAMYEL sensor (A,B) and in mLTC-1 cells transiently expressing 
CAMYEL sensor alone (C) or not (D). Cells were stimulated 30 minutes with increasing doses (A,C and D) or 
immediately with the indicated doses (B) of rhCG and rhLH, before cAMP production was measured by BRET 
(A,B and C) or HTRF (D). Data are means ± SEM of 3–8 independent experiments. The kinetic curves in panel 
B are representative of 3 experiments performed in triplicate.
Responses
rhCG rhLH
Emax EC50 n Emax EC50 n
cAMP 0.43 ± 0.02 17.64 ± 6.97 pM 8 0.42 ± 0.01ns 286.49 ± 50.29 pM*** 8
ß-arrestin 2 0.21 ± 0.01 10.26 ± 2.50 nM 5 0.14 ± 0.01** 129.10 ± 69.96 nM* 5
Cre-reporter assay 222.12 ± 9.64 37.47 ± 4.94 pM 3 214.03 ± 9.58ns 215.45 ± 20.81 pM*** 3
Table 1. Efficacy (Emax) and efficiency (EC50) of rhCG and rhLH on LH/CGR measured in different assays in 
HEK293 cells. The Emax values are represented as hormone-induced BRET changes (for cAMP and ß-arrestin 2) 
and relative luciferase activity × 103 (for Cre-reporter assay). Statistical analyses were performed with unpaired 
t-test (***p < 0.001; **p < 0.01; *p < 0.05, ns non-significant).
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It is worth noting that consistent with HEK293 cell data, rhCG and rhLH promoted similar maximal cAMP 
responses in mLTC-1 cells despite the differences in their potencies confirming that both are full agonists for 
cAMP pathway (Fig. 1C and D) (Table 2).
β-arrestin 2 recruitment and activation. β-arrestins are known to play important roles not only in 
desensitization/internalization of GPCRs but also in their signaling12–14. Here, we examined the recruitment 
of β-arrestin 2 upon exposure to increasing doses of rhCG and rhLH using BRET technology as previously 
reported10, 11. HEK293 cells were transiently co-transfected with plasmids coding for hLH/CGR-Rluc8 and for 
yPET-β-arrestin 2 fusion proteins and BRET measurements were performed in a dose-dependent manner and in 
living cells. As shown in Fig. 2A, rhCG and rhLH stimulation significantly promoted β-arrestin 2 recruitment to 
hLH/CGR in a dose-dependent manner with the EC50 value of rhCG 12 times lower than that of rhLH (p = 0.044; 
n = 5) (Table 1). The significant difference in the two hormone potencies is consistent with the data on cAMP 
pathway (Fig. 1) (Table 1). Low potencies were found for both hormones on β-arrestin recruitment compared to 
cAMP responses consistent with our previous report indicating that a higher receptor occupancy rate is needed 
Responses
rhCG rhLH
Emax EC50 n Emax EC50 n
cAMP (BRET) 0.45 ± 0.02 68.82 ± 22.30 pM 5 0.44 ± 0.02ns 459 ± 105.35 pM** 5
cAMP (HTRF) 100% 97.37 ± 47.15 pM 3 102 ± 5.8%ns 1980.33 ± 868.64 pM* 3
Cre-reporter assay 1910 ± 111 24.97 ± 16.20 pM 4 1971 ± 168ns 317.62 ± pM* 4
Progesterone 100% 19.72 ± 4.28 pM 3 49.78 ± 2.90%*** 305.83 ± 25.22 pM** 3
Testosterone 100% 2.19 ± 0.91 pM 4 93.33 ± 6.5%ns 29.05 ± 6.90 pM** 4
Table 2. Efficacy (Emax) and efficiency (EC50) of rhCG and rhLH on LHR measured in different assays in 
mLTC-1 cells. The Emax values are represented as hormone-induced BRET changes (for cAMP by BRET), % of 
rhCG-induced response (for cAMP by HTRF, progesterone and testosterone) and relative luciferase activity 
(for Cre-reporter assay). Statistical analyses were performed with unpaired t-test (***p < 0.001; **p < 0.01; 
*p < 0.05, ns non-significant).
Figure 2. LH/CGR-promoted β-arrestin 2 recruitment and activation in HEK293 cells. HEK293 cells 
transiently co-expressing either hLH/CGR-Rluc8 and yPET-β-arrestin 2 (A and B) or wildtype hLHR/CGR and 
Rluc8-β-arrestin 2-RGFP (C) were stimulated 30 minutes with increasing doses (A and D) or immediately with 
the indicated doses (B) or 0.25 µM (C) of rhCG and rhLH before BRET was measured. Data are means ± SEM 
of 3–5 independent experiments. The kinetic curves in panel B are representative of 3 experiments performed in 
triplicate.
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to engage β-arrestin recruitment10, 11. Interestingly, our data reveal that rhLH seems to exhibit partial agonistic 
activity compared to rhCG (p = 0.0104; n = 5) (Fig. 2A) (Table 1). Real-time kinetic analysis of BRET signals in 
cells stimulated with either EC50 (10 nM and 50 nM) or saturating (500 nM) concentrations of both rhCG and 
rhLH, showed a significant difference in β-arrestin 2 recruitment kinetics between the two hormones with t1/2 
values of 6.15 ± 0.17 min and 13.32 ± 0.32 min with 500 nM of rhCG and rhLH, respectively (Fig. 2B). These 
kinetic data are in keeping with the partial activity of rhLH compared to rhCG on β-arrestin recruitment even at 
the saturating doses of the hormone (Fig. 2B).
Next, we investigated the impact of hLH/CGR activation by rhCG or rhLH on β-arrestin 2 conformations 
using a previously reported double brilliance β-arrestin 2 BRET sensor40–42. In this sensor, β-arrestin 2 is fused 
with both a BRET donor and acceptor. Therefore, any change in the intramolecular BRET signals reflects a con-
formational change in β-arrestin 2. Interestingly, real-time kinetic analyses with 0.25 µM of hormones showed 
stronger induction of conformational changes under LH than rhCG treatment within β-arrestin sensor (Fig. 2C). 
However, no significant difference in the half-time (around 12 minutes) between the two hormones was observed 
(Fig. 2C). Such a difference between rhCG and rhLH on β-arrestin conformation was observed at different con-
centrations of the hormones (Fig. 2D). Together, the data with β-arrestins are consistent with the different sensi-
tivity of LH/CGR to rhCG and rhLH suggesting the existence of hormone-specific receptor conformation which 
could in turn impact β-arrestin conformation.
LHR-promoted integrated responses. To further assess the impact of the differences elicited by the two 
hormones at the transductional level, we sought to measure downstream read-outs in the signaling pathways. In 
HEK293 cells, we used a cre-dependent reporter gene, pSOM-Luc, as an indicator of LH/CGR-induced transcrip-
tional activation11, 43. As shown in Fig. 3A, both hormones showed clear dose-dependent activation of luciferase 
activity with EC50 of rhCG almost 5 times lower than that of rhLH (p = 0.0004; n = 3) (Table 1). By contrast, the 
two hormones showed similar maximal responses expressed in relative luciferase activity (Fig. 3A) (Table 1). 
These observations are consistent with the cAMP data in HEK293 and mLTC-1 cells as shown in Fig. 1.
Next, we explored more distal responses to rhCG and rhLH in mLTC-1 cells endogenously expressing LHR. 
For this, we measured pSOM-Luc activation in Cre reporter assay (Fig. 3B), progesterone (Fig. 3C) and testoster-
one (Fig. 3D) responses upon stimulation with increasing doses of rhCG and rhLH. In the Cre reporter assay, we 
observed a significant shift (p = 0.0202; n = 4) similar to the one observed in HEK293 cells with rhCG being more 
Figure 3. LH/CGR-promoted integrated responses in HEK293 and mLTC-1 cells. (A) HEK293 transiently 
co-transfected with plasmids coding for LH/CGR and pSOM-Luc reporter gene were stimulated 6 hours with 
increasing doses of rhCG and rhLH before luciferase activity was measured (A). mLTC-1 cells transiently 
transfected with plasmid coding pSOM-Luc reporter gene were stimulated 6 hours with increasing doses 
of rhCG and rhLH before luciferase activity was measured (B). For LHR-mediated steroid production, 
mLTC-1 cells were stimulated 3 hours with increasing doses of rhCG and rhLH and the supernatant levels of 
progesterone (C) and testosterone (D) were measured by ELISA or HTRF, respectively. Data are means ± SEM 
of 3–5 independent experiments performed in single or duplicate.
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potent than rhLH, (Fig. 3B) (Table 2). In progesterone assay, we found that the EC50 of rhCG was approximately 
15 times lower than that of rhLH (p = 0.0011; n = 3) (Fig. 3C) (Table 2). This observation is in agreement with 
cAMP data (Fig. 1), β-arrestin data (Fig. 2A), and Cre-luciferase-based cAMP assay (Fig. 3A) data confirming 
that rhCG is more potent than rhLH on LH/CGR. Interestingly, the maximal progesterone produced by rhLH 
was only 49.8 ± 2.9% (p < 0.0001; n = 3) of that promoted by rhCG, indicating a partial response of rhLH on 
progesterone synthesis (Fig. 3C) (Table 2). Such a partial response of rhLH is consistent with that observed for 
LH/CGR-promoted β-arrestin 2 recruitment (Fig. 2A). In the case of testosterone, we also observed a higher 
potency of rhCG (≈13 folds) compared to rhLH, (p = 0.0084; n = 4) (Fig. 3D) (Table 2), which is consistent with 
progesterone data (Fig. 3C), cAMP responses in HEK293 and mLTC-1 cells (Fig. 1A and C) as well as β-arrestin 
in HEK293 cells (Fig. 2A). We also noticed that both hormones were clearly more potent at activating testosterone 
than progesterone production (Table 2). However, by contrast to progesterone response, there was no signifi-
cant difference in the maximal testosterone response between the two hormones (p = 0.3848; n = 4) (Fig. 3D). 
Together, this illustrates the complexity of the steroidogenic pathways engaged by LHR, suggesting that distinct 
signaling pathways might control the production of progesterone and testosterone as previously proposed11.
Implication of β-arrestins in steroid production. The similarity in the partial effects of rhLH on 
β-arrestin (Fig. 2A) and progesterone (Fig. 3C) responses compared to rhCG suggests that β-arrestins may 
be implicated in progesterone production. Therefore, we examined the contribution of β-arrestin-dependent 
transduction on the control of LHR-mediated steroidogenesis using siRNA-mediated depletion of endogenous 
β-arrestin 1 or β-arrestin 2 in mLTC-1 cells. For this, control, β-arrestin 1 or β-arrestin 2-depleted mLTC-1 cells 
were exposed to increasing doses of rhCG (Fig. 4A,C and E) and rhLH (Fig. 4B,D and F). Progesterone and testos-
terone were measured in parallel in the same cells. Our data confirm the partial progesterone response mediated 
by rhLH compared to rhCG as shown in Fig. 3B. However, on testosterone production there was no difference 
in hormone efficacy but rhCG was more potent that rhLH confirming the data shown in Fig. 3D. Interestingly, 
we observed that the depletion of both β-arrestin 1 and β-arrestin 2 led to a partial decrease in the progesterone 
production induced by rhCG (Fig. 4A) and rhLH (Fig. 4B) compared to control siRNA-transfected mLTC-1 
cells. The statistical analysis demonstrates the significance of β-arrestin depletion for both rhCG (p < 0.0001 for 
siRNA β-arrestin 1 and p = 0.0233 for siRNA β-arrestin 2; n = 3) and rhLH (p = 0.001 for siRNA β-arrestin 1 
and p = 0.0275 for siRNA β-arrestin 2; n = 3) with siRNA β-arrestin 1 being more efficient. Moreover, β-arrestin 
depletion showed stronger inhibitory effects on testosterone production mediated by either rhCG (Fig. 4C) 
or rhLH (Fig. 4D) (p < 0.0001 for siRNA β-arrestin 1 and β-arrestin 2; n = 3). The specificity of the effects of 
β-arrestin depletion on steroidogenesis was demonstrated by measuring cAMP production in parallel in the 
siRNA-transfected mLTC-1 cell samples. As anticipated, the depletion of β-arrestin 1 or 2 had no effect on rhCG- 
(Fig. 4E) or rhLH- (Fig. 4F) mediated cAMP production whatever the dose of the hormones used, thus ruling 
out toxic or side effects that the siRNA may have exerted on these cells. Together, these data suggest the partial 
implication of β-arrestins in LHR-mediated progesterone and argue for a significance of β-arrestin bias between 
rhCG and rhLH in HEK293 cells.
Calculation of biases between rhCG and rhLH. Biases were calculated using data-fitting of the opera-
tional model37 and the procedure previously detailed11, 38. Bias factor combines both efficacy and potency to quan-
tify the imbalance between two cell responses for an agonist, in comparison to a reference agonist on the same 
receptor and within the same cell model. For this, we used rhCG as the reference ligand for the different assays in 
both HEK293 and mLTC-1 cells (Table 3). A bias exists if the bias factor is significantly different from 1 (unpaired 
t-test). In HEK293 cells, we found that rhLH, compared to rhCG, was significantly biased towards cre-dependent 
reporter gene against both β-arrestin 2 and cAMP (Table 3). To some extent, rhLH is also biased towards 
β-arrestin 2 against cAMP (Table 3). In other words, in HEK293 cells, rhLH preferentially induces: Cre-dependent 
transcription > β-arrestin 2 recruitment > cAMP, compared to rhCG. This finding may be considered counter-
intuitive since Cre reporter assay and cAMP are connected by the activation of cAMP response element-binding 
protein (CREB) which is primarily under the control of cAMP/PKA pathway. However, it is also well documented 
that CREB activation integrates other signaling pathways such as ERK and p38 MAPKs, p90RSK or CAMKs. In 
that sense, Cre reporter assay can be viewed as a read out which integrates several signalling pathways, not just 
cAMP/PKA. In mLTC-1 cells, rhLH-promoted response was significantly biased towards cAMP compared to 
progesterone and testosterone and a moderate bias appeared towards testosterone compared to progesterone 
(Table 3). This means that, in mLTC-1 cells, rhLH preferentially induces: cAMP > testosterone > progesterone, 
compared to rhCG. Overall, these bias calculations confirm the differences between the pharmacological profiles 
of rhCG and rhLH on the different responses in HEK293 and mLTC-1 cells.
Discussion
In the present work, we investigated the differential activity exerted by rhCG and rhLH upon binding to their 
common receptor, human LH/CGR transiently expressed in HEK293 cells or mouse LHR endogenously 
expressed in mLTC-1 cells. The attention was focused on comparing their pharmacological profiles on the het-
erotrimeric G proteins, Gαs/cAMP pathway as well as β-arrestins and their contribution to signal transduction 
mechanisms leading to the modulation of steroidogenesis. For cAMP, rhCG was more potent than rhLH but both 
hormones promoted full activation of the receptor at saturating doses in HEK293 as well as mLTC-1 cells. A sim-
ilar difference in potency was also observed on β-arrestin recruitment in HEK293 cells, however an interesting 
difference was also found in hormone efficacy since rhLH promoted only a partial response. We also examined 
the action of rhLH and rhCG on progesterone and testosterone production in mLTC-1 cells confirming the 
higher potency of rhCG compared to rhLH. Interestingly, we found that rhLH exhibited a partial activity for 
progesterone compared to rhCG while both fully promoted testosterone production. Altogether, our data show 
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that rhCG is more potent than rhLH on LH/CGR activity in HEK293 and mLTC-1 cells which is consistent with 
previous studies in COS-7 and granulosa cells33. Moreover, the partial agonism of rhLH on LH/CGR on both 
β-arrestin recruitment and progesterone production suggests a link between these two events. It can be observed 
Figure 4. Implication of β-arrestins in LH/CGR-promoted steroid production in mLTC-1 cells. mLTC-1 
cells were transiently transfected with either control, β-arrestin 1 or β-arrestin 2 siRNAs. Then, cells were 
stimulated 3 hours with increasing doses of rhCG (A,C and E) and rhLH (B,D and F) before progesterone (A 
and B), testosterone (C and D) and cAMP (E and F) productions were measured. The maximal rhCG-mediated 
responses obtained at 10 nM with control siRNA was taken as 100%. Data are means ± SEM of 3 independent 
experiments performed in duplicate.
HEK293 cells Bias factor mLTC-1 cells Bias factor
ß-arrestin 2/cAMP 1.81 (p = 0.0655) cAMP/Progesterone 5.25 (p = 0.0034)
Cre-reporter assay/cAMP 4.84 (p = 0.0000177) cAMP/Testosterone
2.39 
(p = 0.0301)
Cre-reporter assay/ß-arrestin 
2 2.67 (p = 0.00988) Testosterone/Progesterone
2.19 
(p = 0.0617)
Table 3. Bias factor on the different responses in HEK293 and mLTC-1 cells. The bias factor values of each 
response pair reflect the biased agonism of rhLH towards the first response compared to the second, all in 
comparison to rhCG taken as the reference hormone.
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that the minimal doses of rhCG or rhLH promoting full testosterone responses trigger only very partial (20–25%) 
progesterone response. It reflects the physiological role of hCG, which serves to induce progesterone synthesis, 
while LH is a mediator of testosterone production. Indeed, in Leydig cells, androgen synthesis occurs mainly via 
the so-called Δ5-pathway, while progesterone is a “parallel accumulation product” falling within the relatively 
ineffective Δ4-pathway46. We could speculate that, differently to hCG, LH is fully active on the Δ5- rather than 
Δ4-pathway. The results provided by β-arrestins silencing by siRNA (Fig. 4) agree with this view, since these mol-
ecules are required to fully support LH/hCG-mediated testosterone but not progesterone synthesis.
In the present study, we are using immortalized cell lines as model systems. It is important to determine to 
what extent the data obtained in these cells can be indicative of the physiological mechanisms that occur in the 
ovary. In fact, the transduction mechanisms occurring directly downstream of the ligand-LH/CGR complex, such 
as Gαs coupling and cAMP production or β-arrestins recruitment, have been reported to be mostly reproducible 
across a wide range of cell models. This is corroborated by previous observation in human and goat primary 
granulosa cells33–35, in transfected COS-7 and human immortalized granulosa cell lines33, as well as in mouse 
primary Leydig cells47. In all these cell systems, hCG treatment results in higher cAMP production than LH. One 
can rationalize that these mechanisms largely rely on the ligand and receptor amino acid sequence, conforma-
tional changes, etc., all properties that are nearly identical in granulosa and Leydig cells, as well as in transfected 
cell lines. Indeed, we demonstrated that hCG is more potent than LH, in terms of cAMP production, in all these 
cell models. The amino-acid changes existing between the rodent and the human receptor have been shown to 
have minimal, if any, effects on hLH or hCG binding rates23. According to this principle, downstream outputs, 
which are located farer from the ligand-receptor complex, may lead to more cell type-dependent variations. This 
is indeed the case when comparing the mLTC-1 cell line used in the present paper and the primary mouse Leydig 
cells, which were used in another recently published study47. In primary Leydig cells, we demonstrated that LH 
and hCG treatment results in different cAMP production but equal testosterone dose-response curves, whereas in 
mLTC-1 cells, hCG is more potent than hLH at inducing testosterone production. Taken together, these findings 
indicate that hCG has a higher steroidogenic potential than LH, even if, in physiological settings, their effects may 
differ as a consequence of tissue-specific modulatory events.
From the molecular point of view, LH- and hCG-induced signaling is known to be differently modulated by 
exon 10 deletion in LH/CGR, which results in structural and spatial rearrangements at the hinge region of the 
receptor32. In the presence of this deletion, LH signaling is impaired while hCG signaling remain unchanged, 
suggesting divergences between hCG- and LH-receptor interactions and actions. In addition, hCG and LH were 
recently shown to interact differently with the hinge region of the receptor25 and only hCG is capable of inducing 
both cis- and trans-activation of human LH/CGR26. Moreover, both hCG and LH were reported to have similar 
association rate on rat LHR (3 × 108 M−1.min−1) but different dissociation rate (25 h for hCG and ∼9 h for hLH) 
constants indicating higher residence time of hCG on its receptor23. Such a finding was recently supported by 
dissociation assays on gonadotropin-promoted cAMP production in mLTC-1, suggesting weaker dissociation of 
hCG from LHR compared to hLH36. Furthermore, our real-time cAMP measurements clearly showed differences 
in the kinetics of the two hormones with rhCG inducing faster cAMP responses than rhLH. This indicates the 
relationship between the difference in hormone potencies and the kinetics of their induced responses, suggesting 
a link between pharmacological bias and response kinetics as recently reported48. Collectively, these observations 
suggest that the slower dissociation rate of rhCG compared to that of rhLH and/or the differences in the con-
formations of hormone-receptor complexes may explain the differences between rhCG- and rhLH-promoted 
responses.
Our quantitative pharmacological profiling revealed striking peculiarities when comparing the maximal 
responses elicited by the two gonadotropins on the different readouts. Indeed, even though identical maximal 
cAMP responses were reached with either gonadotropin, whatever the cell type (HEK293 and mLTC-1), rhLH led 
to significantly weaker maximal β-arrestin 2 recruitment and progesterone production than rhCG. Thus, it could 
be hypothesized that β-arrestin is a limiting factor for maximal progesterone production. In other words, rhLH 
like rhCG is full agonist on LH/CGR for cAMP and testosterone production, whereas it is only partial agonist for 
β-arrestin recruitment and progesterone production. The fact that rhLH was full agonist on testosterone and had 
only a partial efficacy on progesterone further demonstrates that the full action of the hormone, in Leydig cells, 
is exerted via Δ5-pathway, through 17-OH-pregnenolone production (instead of progesterone) as a precursor of 
testosterone. This is also supported by our recent study using two FSHR and LHR negative allosteric modulators 
(NAMs) showing differential antagonism of the two NAMs on progesterone and testosterone11. Moreover, we 
observed that both hormones differently affected the conformation of β-arrestin 2 as assessed in double brilliance 
BRET assay used as conformational sensor of β-arrestins40, 42. In this assay, rhCG elicited less BRET changes 
within the β-arrestin 2 sensor than rhLH which is consistent with the idea that the two hormones stabilize differ-
ent conformations of β-arrestin as shown for other GPCRs depending on the ligands applied41, 49, 50.
Together, these observations strongly suggest that rhCG and rhLH differentially recruit β-arrestins and activate 
downstream pathways which may control progesterone production. We hypothesized that β-arrestin-dependent 
transduction could be involved in the control of the balance between progesterone and testosterone production as 
recently reported11. Supporting this view, we demonstrated that depletion of endogenous β-arrestins in mLTC-1 
cells using selective siRNA led indeed to partially but significantly reduced progesterone production. This sup-
ports the link between the partial agonism of rhLH on both β-arrestin and progesterone production. In contrast, 
such depletion had no effect on hormone-promoted cAMP production in mLTC-1 excluding a role of β-arrestins 
in cAMP production as expected. Altogether, our results support to the concept of biased agonism exerted by 
rhCG and rhLH and bear the notion that LH/CGR can discriminate the binding of the two hormones, thereby 
triggering different transduction mechanisms hence intracellular responses. In addition to the pharmacologi-
cal profiling of rhCG and rhLH, our study and the bias analysis reveal the importance to quantify the balance 
between the different signaling pathways for each hormone. The fact that both hormones naturally coexist but to 
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different extent and at different stages during folliculogenesis and pregnancy, raises intriguing prospects. The use 
of these hormones in assisted reproduction could also be impacted by the present findings. Finally, the impact 
of our study goes beyond the gonadotropin receptors and reproduction since it describes an interesting example 
of biased signaling involving two endogenous hormones activating a common GPCR. This further demonstrates 
the physiological relevance of the signaling bias at GPCRs with strong impact on our understanding of GPCR 
pharmacology and signaling and potential applications in drug discovery programs51, 52.
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